REG - BkofA Merrill Lynch Horizon Therapeutics - 20230824_HORIZON THERAPEUTICS PLC_38.5 (a)_IE_MLI

AmgenAnnouncement

25/08/2023 11:31

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230825:nRSY4832Ka&default-theme=true

RNS Number : 4832K  Bank of America Merrill Lynch  25 August 2023

FORM 38.5(a)

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED

INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY

 

 1.  KEY INFORMATION

 Name of exempt principal trader:            Merrill Lynch International
 Company dealt in                            HORIZON THERAPEUTICS PLC
 Class of relevant security to which the     Common - IE00BQPVQZ61

dealings being disclosed relate(Note 1)
 Date of dealing                             24/08/2023

Merrill Lynch International

 Company dealt in

HORIZON THERAPEUTICS PLC

 Class of relevant security to which the

dealings being disclosed relate(Note 1)

Common - IE00BQPVQZ61

 Date of dealing

24/08/2023

 

 2.  DEALINGS (Note 2)

 (a)  Purchases and sales

 Total number of relevant securities acquired  Highest price paid (Note 3)  Lowest price paid (Note 3)

 

 Total number of securities disposed  Highest price received (Note 3)  Lowest price received (Note 3)

 

 (b)  Derivatives transactions (other than options transactions)

 Product name,  Nature of transaction        Number of relevant securities  Price per unit

e.g. CFD
(Note 4)                    (Note 5)
(Note 3)
 Swaps          Increasing a Short Position  1                              106.02 USD

 

 (c)  Options transactions in respect of existing relevant securities

 (i)  Writing, selling, purchasing or varying

 Product name, e.g. call option  Writing, selling, purchasing, varying etc.  Number of securities to which the option relates (Note 5)  Exercise price  Type, e.g. American, European etc  Expiry date  Option money paid/ received per unit (Note 3)
 N/A                             N/A                                         N/A                                                        N/A             N/A                                N/A          N/A

 

 (ii)  Exercising

 Product name,      Number of securities  Exercise price per

e.g. call option
unit (Note 3)
 N/A                N/A                   N/A

 

 3.  OTHER INFORMATION

 

 Agreements, arrangements or understandings relating to options or derivatives

 

 Full details of any agreement, arrangement or understanding between the person

 disclosing and any other person relating to the voting rights of any relevant

securities under any option referred to on this form or relating to the voting
 rights

or future acquisition or disposal of any relevant securities to which any
 derivative

referred to on this form is referenced. If none, this should be stated.
 Collateral Delivery of 108,943 shares
 NaN shares returned
 Rehypothecation of 98,745 shares
 11,119 shares returned
 21,317 shares returned
 NaN shares returned

 

 Date of disclosure             25/08/2023
 Contact name                   Frank Lui
 Telephone number               +44207 996 6418
 Name of offeree/offerer with   AMGEN INC

which connected
 Nature of connection(Note 6)   Advisor to - AMGEN INC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ITPPPUAPRUPWUBA